Pelican-Cancer-Foundation-logos
Donate Now
Search
Pelican-Cancer-Foundation-logos

Dedicated to helping patients with bowel and liver cancer live well for longer

Donate Now
Search
  • Home
  • About us
    • About us
    • What we do
      • Our achievements
      • The Future
    • Who we are
      • Trustees
      • Our Team
      • Patrons
      • Annual Accounts
    • Partnerships
    • Vacancies
    • News
  • Education
    • Pelican OReCO
      • OReCO On-line Resources
      • OReCO Partners & Sponsors
      • Pelican OReCO Workshops
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
    • LARS
    • Sponsors
      • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Films
  • Research
    • MERCURY 3
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Previous Research Areas
      • Prostate Cancer Research
        • Prostate cancer
        • Focal therapy and HIFU research
        • MRI research for prostate cancer
        • Prostate cancer colloquiums
        • FORECAST
        • Trachtomap
        • Papers of interest
      • Bladder cancer research
        • Bladder cancer
        • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for research applicants
      • Peer Review Panel Terms of Reference
      • Research Review Panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Pseudomyxoma peritonei
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Shares
      • In memory
    • Fundraise for us
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
    • Leave a Gift in your Will
    • Become a Corporate Partner
    • Trusts, Foundations & Philanthropy
    • Tell us your story
  • Contact us

The SPECC National Development Programme has successfully completed

December 15, 2017 by pelicanadmin

Significant Polyps and Early Colorectal Cancer – SPECC

Thanks to excellent guidance from our steering group we started the SPECC National Development Programme workshops in London in November 2015.  Since then we have run 14 more workshops across England, Wales, Scotland and Ireland – making it an international programme.

The aims of the programme were to:

  • Define a significant polyp and identify an early colorectal cancer
  • Recognise a SPECC and how this is best achieved
  • Document and describe SPECC to better aid multi-disciplinary decision making
  • Plan carefully – ‘think twice and cut once’, making sure that the first shot it the best as these are ‘high value lesions’. Careful decision making about the use of biopsy and whether they add value. Take time and use regional and national resources, refer to experts – ‘another day, another endoscopist, another hospital’
  • Treatment – first treatment gives the best outcome. Low risk lesions can be safely removed endoscopically. MDT decision must include expert endoscopist

There was a core faculty of 10 with another 90 specialists joining the SPECC faculty to help with presentations and case studies.

1,237 clinicians attended a workshop over the 25 months that the programme ran.  These people came from 178 hospitals in England, Wales, Scotland, Northern Ireland and Ireland.  A third of those attending were consultant surgeons.

The programme was free for 6 core members of each colorectal MDT as long as this included a surgeon, gastroenterologist, pathologist, radiologist and specialist nurse.

Feedback:

‘Very interesting, well organised, fascinating’

‘Very high standard of talks & discussion’

‘Imaging and precision improves definitive treatment’

‘Think twice, cut once’

‘Super informative day – well done Pelican’

‘This was an excellent meeting and a lot of very interesting topics – valuable information for MDT management’

‘More awareness of polyp presentation and input of MDT in management decisions’

Achievement

Nearly every hospital throughout the UK and Ireland has now spent time considering this small but challenging cohort of patients who present with SPECC.  The multi-disciplinary members of the MDT have a greater awareness of the difficulties and uncertainties that SPECC present and will have more confidence within their MDT discussion about the local treatments available and where to refer if need be.

Finally – we would like to thank everyone for their help.  This programme was supported mainly by the generosity of Pelican charitable donations. We are very grateful for industry sponsorship – Norgine supported all of the workshops, Exact Sciences, Medtronic and Applied Medical also attended a small number of meetings.

Publication

Following the completion of the SPECC programme, we were delighted to work with members of the Faculty to compile a supporting supplement for publication – https://onlinelibrary.wiley.com/toc/14631318/2019/21/S1. The publication is 65 pages, made up of 16 supplement articles and the key messages from the Faculty. It is in Free Access format, allowing anyone to view and download the papers, ensuring that the key reference points from the national programme are available for everyone to read.

Filed Under: SPECC News, Uncategorized

Stay in touch

Sign up to hear from us
Donate Now

© 2023 Pelican Cancer Foundation - all rights reserved

  Registered Charity Number: 1141911 -  Privacy Policy